Osivax and GC Biopharma announced a new alliance focused on developing a next-generation influenza vaccine. The vaccine is set to combine OVX836 and GC FLU. Osivax gained the rights to advance a combination shot.
Older adults are facing four vaccine decisions this fall, while the federal immunization calendar continues to carry a 2025 date. Flu and pneumonia deaths have dropped for 25 years, but one American age group saw an increase.